Ketamine is under clinical development by Seelos Therapeutics and currently in Phase I for Treatment Resistant Depression. According to GlobalData, Phase I drugs for Treatment Resistant Depression have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Ketamine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ketamine (Wafermine) is under development for the treatment of acute and severe postoperative pain in Hallux valgus (Bunion) and abdominoplasty and also under development for major depressive disorder, post-traumatic stress disorder and treatment resistant depression. It is formulated as a wafer and is administered through sublingual route. It acts by targeting N-methyl-D-aspartate (NMDA) receptor. The drug candidate is developed based on WaferiX sublingual technology.
Seelos Therapeutics overview
Seelos Therapeutics (Seelos) is a clinical-stage biopharmaceutical company that focuses on developing novel technologies and therapeutics for the treatment of central nervous system (CNS) and other rare disorders. Its lead programs include SLS-002, SLS-005, and pipeline products include SLS-004, SLS-008, SLS-007, SLS-010 and SLS-012. Seelos pipeline products find application in treating various multiple CNS disorders including parkinson’s disease, sanflippo syndrome, suicidality post-traumatic stress disorders, major depressive disorders and other diseases such as atopic dermatitis, asthma, and pediatric esophagitis. It operates along with its subsidiaries. Seelos is headquartered in New York, the US.
For a complete picture of Ketamine’s drug-specific PTSR and LoA scores, buy the report here.